Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday

Key Points

• Cartesian Therapeutics is set to announce its quarterly earnings on August 14, with analysts expecting a loss of ($0.77) per share and revenue of $0.77 million.
• The company's stock has a market cap of approximately $292.76 million and has experienced price fluctuations, with a one-year low of $8.46 and high of $26.50.
• Recent analyst reports show a general buy rating for Cartesian Therapeutics, with a target price averaging around $40.00.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Cartesian Therapeutics to post earnings of ($0.76) per share and revenue of $0.77 million for the quarter.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of ($0.76) by $1.26. The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.77 million. On average, analysts expect Cartesian Therapeutics to post $5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cartesian Therapeutics Price Performance

Shares of Cartesian Therapeutics stock traded down $0.01 during trading on Friday, hitting $10.53. The company's stock had a trading volume of 32,141 shares, compared to its average volume of 59,691. Cartesian Therapeutics has a 52 week low of $8.46 and a 52 week high of $26.50. The stock has a market cap of $273.30 million, a price-to-earnings ratio of -0.20 and a beta of 0.44. The stock has a 50-day moving average price of $11.47 and a two-hundred day moving average price of $13.37.

Institutional Trading of Cartesian Therapeutics

An institutional investor recently raised its position in Cartesian Therapeutics stock. Rhumbline Advisers raised its position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 27.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,006 shares of the company's stock after acquiring an additional 2,805 shares during the quarter. Rhumbline Advisers owned approximately 0.05% of Cartesian Therapeutics worth $171,000 at the end of the most recent quarter. Institutional investors own 86.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on RNAC shares. Wedbush started coverage on shares of Cartesian Therapeutics in a research report on Wednesday, July 9th. They set an "outperform" rating and a $38.00 price target on the stock. Needham & Company LLC cut their price target on shares of Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Cartesian Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $40.00.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.